Partial epigenetic reprogramming (ER-100)
Partial epigenetic reprogramming (Life Biosciences ER-100). Aging itself. Reviewed Jul 2026.
A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.
What it is
Gene therapy that resets epigenetic marks to make old cells behave younger without erasing cell identity. First-in-human study cleared by the FDA in Jan 2026, starting in the eye (glaucoma / NAION).
The evidence
FDA IND cleared; Phase 1 safety/tolerability underway. Animal data shows restored vision and tissue rejuvenation.
What you can do today
Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.
Sources
- Coverage, not a sourcefortune.com
No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.
Change history
No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.
Related
More in Aging itself
- Rapamycin for longevityExtends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.
- Acarbose for longevityOne of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
- VO₂max and strength for longevityIn large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
- RentosertibSix aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
- Senolytics (dasatinib, quercetin, fisetin)Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
- Therapeutic plasma exchange for agingA small trial lowered biological-age scores by about 1.3 years, a surrogate marker, and there is no outcome data.